Search Term:

*


November 14, 2017: New modules enable fully continuous processes in UF/DF processing steps, available in a range of size formats for use in one or more locations of a continuous mAb downstream purification process

January 29, 2018: New name reinforces Pall's commitment to providing standard configurable single-use, stainless steel and hybrid technologies for fed-batch and continuous processes across upstream, downstream and formulation and filling applications in biotech

November 21, 2017: Introducing a new and robust solution for the economic clarification of mAb (monoclonal antibody) cell cultures without the need for centrifugation or process additives

January 16, 2018: Product identified by key industry publication as one of the most exciting commercial drug development and manufacturing technologies, tools or services released during the past year

February 27, 2018: New offices, labs and manufacturing space for development and optimization of customer processes

November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing

April 15, 2018: Patrnership to bring together Artesyn Biosolutions' valves and fluid handling technologies with Pall's Allegro solutions including bioreactors, range of downstream automated equipment and mixers to enable customers to implement efficient single-use manufacturing lines

September 3, 2018: Celltheon and Pall to provide an integrated, cost-effective, time efficient end-to-end solution for research and bioproduction to expedite drug development and provide solutions for unmet needs in bioprocessing

July 23, 2018: New partnership to integrate novel biologics and biosimilars process know-how and regulatory experience from molecule selection to full commercialization, with efficient upstream and downstream process equipment and facility design solutions for manufacturers

April 8, 2018: Product identified as key to making a great contribution to the advancement of upstream and downstream bioprocessing

September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development

September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing

October 5, 2016: New collaboration to deliver complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs), to accelerate product development, reduce clinical translation timelines and streamline the commercialization pathway for stem cell-based therapies

July 17, 2018: Agreement will meet increased demand for more targeted and personalized medicines currently driving growth and development in the mAb manufacturing market and offer a complete solution to customers

January 18, 2016: New chromatography media (sorbent) will offer high dynamic binding capacity, good flow performance and optimal alkali stability for reuse

September 11, 2015: Pall manufacturing facility in Ilfracombe, UK is singled out for its exceptional health and safety management systems

October 4, 2016: Multiple breakthrough technologies announced to enable integrated, process-scale continuous production of biotherapies in single-use format

April 26, 2016: This new product will eliminate reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and create a continuous feed stream for direct integration with Pall's full portfolio

October 13, 2016: Introducing a reliable, robust, universal single-use fluid handling connector - a genderless technology for the sterile connection of two fluid paths even in uncontrolled environments

July 26, 2017: Announcing a new bioreactor control system - the first in Pall's next generation of unifying technologies for a seamless, fully controlled, and value-based user experience